Search

The adenosine A.sub.1 receptor (A.sub.1R) is a promising therapeutic target for non-opioid analgesic agents to treat neuropathic pain.sup.1,2. However, development of analgesic orthosteric A.sub.1R agonists has failed because of a lack of sufficient on-target selectivity as well as off-tissue adverse effects.sup.3. Here we show that [2-amino-4-(3,5-bis(trifluoromethyl)phenyl)thiophen-3-yl)(4-chlorophenyl)methanone] (MIPS521), a positive allosteric modulator of the A.sub.1R, exhibits analgesic efficacy in rats in vivo through modulation of the increased levels of endogenous adenosine that occur in the spinal cord of rats with neuropathic pain. We also report the structure of the A.sub.1R co-bound to adenosine, MIPS521 and a G.sub.i2 heterotrimer, revealing an extrahelical lipid-detergent-facing allosteric binding pocket that involves transmembrane helixes 1, 6 and 7. Molecular dynamics simulations and ligand kinetic binding experiments support a mechanism whereby MIPS521 stabilizes the adenosine-receptor-G protein complex. This study provides proof of concept for structure-based allosteric drug design of non-opioid analgesic agents that are specific to disease contexts. MIPS521, a positive allosteric modulator of the adenosine A.sub.1 receptor, has analgesic properties in a rat model of neuropathic pain through a mechanism by which MIPS521 stabilizes the complex between adenosine, receptor and G protein., Author(s): Christopher J. Draper-Joyce [sup.1] [sup.10] , Rebecca Bhola [sup.2] , Jinan Wang [sup.3] , Apurba Bhattarai [sup.3] , Anh T. N. Nguyen [sup.1] , India Cowie-Kent [sup.2] , Kelly [...]